Literature DB >> 26312894

The role of BUB and CDC proteins in low-grade breast cancers.

Abhik Mukherjee1, Chitra Joseph2, Madeleine Craze2, Eleni Chrysanthou2, Ian O Ellis3.   

Abstract

BACKGROUND: The drivers of neoplasia within low-grade luminal breast cancers remain undelineated. The BUB and CDC family are among kinase genes known recently to help to identify luminal breast cancers with poorer prognosis. Additionally, other CDC kinase genes (CDC42) are associated with luminal A breast cancers with good prognosis. We aimed to investigate the role of these kinases at the protein level within low-grade luminal breast cancers.
METHODS: The Nottingham Tenovus Primary Breast Cancer Series (n=1858) microarrays were immunostained for BUB (BUB1, BUB1B, BUB3) and CDC proteins (CDC2, CDC42) and expression correlated with clinicopathological and molecular variables and patient outcome (SPSS, version 22).
FINDINGS: On χ(2) analysis, cytoplasmic BUB1 and nuclear BUB3 were negatively associated with grade including pleomorphism, mitosis, and Nottingham Prognostic Index, whereas BUB1B was positively associated (p=0·05). BUB1 and BUB3 expression was positively correlated with oestrogen and progesterone receptor expression whereas BUB1B was negatively correlated (p=0·01). CDC42 had strong associations with tumour morphology within the low-grade luminal breast cancers, tubular and lobular (p=0·02). CDC42 nuclear expression revealed negative correlations with basal (CK5) and HER family biomarkers (p=0·02). By contrast, cytoplasmic CDC2 overexpression was associated with high-grade tumours (p=0·01). BUB1, BUB1B, and CDC42 showed significant associations (p=0·04) with breast-cancer-specific survival even at the 15-20-year range, indicating their long-term prognostic potential.
INTERPRETATION: These results suggest that BUB1, BUB3, and CDC42 are key kinases for low-grade luminal tumours whereas BUB1B and CDC2 kinases are preferentially expressed in high-grade disease. High protein expression of BUB1, BUB3, and CDC42 in low-grade breast cancers was associated with longer overall survival whereas lower expression resulted in poorer outcome. FUNDING: Pathological Society of Great Britain and Northern Ireland, National Institute for Health Research.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2015        PMID: 26312894     DOI: 10.1016/S0140-6736(15)60387-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  18 in total

1.  Identification of differentially expressed protein-coding genes in lung adenocarcinomas.

Authors:  Luyao Wang; Shicheng Li; Yuanyong Wang; Zhenxue Tang; Chaolong Liu; Wenjie Jiao; Jia Liu
Journal:  Exp Ther Med       Date:  2019-12-06       Impact factor: 2.447

2.  Bioinformatics analysis reveals three key genes and four survival genes associated with youth-onset NSCLC.

Authors:  Xuan Han; Peng Ren; Shaohua Ma
Journal:  Open Med (Wars)       Date:  2022-07-06

3.  Oral lichen planus and malignant transformation: The role of p16, Ki-67, Bub-3 and SOX4 in assessing precancerous potential.

Authors:  Eduardo Augusto Rosa; Aura Maria Hurtado-Puerto; Denise Pinheiro Falcão; Aline Patricia Brietzke; Luiz Eduardo De Almeida Prado Franceschi; Florlorêncio Figueiredo Cavalcanti Neto; Valdenize Tiziane; Fabiana Pirani Carneiro; Evelyn Mikaela Kogawa; Heitor Moreno; Rivadávio Fernandes Batista Amorim
Journal:  Exp Ther Med       Date:  2018-03-20       Impact factor: 2.447

4.  Integrated analysis reveals key genes with prognostic value in lung adenocarcinoma.

Authors:  Ying-Jian Song; Juan Tan; Xin-Huai Gao; Li-Xin Wang
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

5.  Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis.

Authors:  Kaidi Yang; Jian Gao; Mao Luo
Journal:  Onco Targets Ther       Date:  2019-02-18       Impact factor: 4.147

6.  Identification of five hub genes as monitoring biomarkers for breast cancer metastasis in silico.

Authors:  Yun Cai; Jie Mei; Zhuang Xiao; Bujie Xu; Xiaozheng Jiang; Yongjie Zhang; Yichao Zhu
Journal:  Hereditas       Date:  2019-06-21       Impact factor: 3.271

7.  Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma.

Authors:  David Stahl; Martin Braun; Andrew J Gentles; Philipp Lingohr; Adeline Walter; Glen Kristiansen; Ines Gütgemann
Journal:  Oncotarget       Date:  2017-07-18

8.  Gene co-expression network reveals shared modules predictive of stage and grade in serous ovarian cancers.

Authors:  Qian Sun; Haiyue Zhao; Cong Zhang; Ting Hu; Jianli Wu; Xingguang Lin; Danfeng Luo; Changyu Wang; Li Meng; Ling Xi; Kezhen Li; Junbo Hu; Ding Ma; Tao Zhu
Journal:  Oncotarget       Date:  2017-06-27

9.  MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide.

Authors:  George C Bobustuc; Amin B Kassam; Richard A Rovin; Sheila Jeudy; Joshua S Smith; Beth Isley; Maharaj Singh; Ameya Paranjpe; Kalkunte S Srivenugopal; Santhi D Konduri
Journal:  Oncotarget       Date:  2018-07-03

10.  BUB1 promotes proliferation of liver cancer cells by activating SMAD2 phosphorylation.

Authors:  Li-Jing Zhu; Yan Pan; Xiao-Ying Chen; Pan-Fei Hou
Journal:  Oncol Lett       Date:  2020-03-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.